Influence of Age on the Effectiveness and Duration of Protection of Vaxzevria and CoronaVac Vaccines: A Population-based Study

Overview

Journal Lancet Reg Health Am

Date 2021 Dec 27

PMID 34957437

Citations 49

Authors

Thiago Cerqueira-Silva

Vinicius de Araujo Oliveira

Viviane S Boaventura

Julia M Pescarini

Juracy Bertoldo Junior

Tales Mota Machado

Renzo Flores-Ortiz

Gerson O Penna

Maria Yury Ichihara

Jacson Venancio de Barros

Mauricio L Barreto

Guilherme Loureiro Werneck

Manoel Barral-Netto

Affiliations

Soon will be listed here.

Abstract

Background: Aging influences COVID-19 severity and response to vaccination, but previous vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within the elderly age group. Here we analyzed the impact of age on viral vector and inactivated virus vaccines' effectiveness, the main platforms used in low- and middle-income countries.

Methods: We report a retrospective longitudinal study of 75,919,840 Brazilian vaccinees from January 18 to July 24, 2021, evaluating documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19-related hospitalisation, ICU admission, and death. Negative binomial regression models adjusted for sociodemographic characteristics were used for VE estimation.

Findings: The overall analyzes of full vaccination showed VE against hospitalisation, ICU admission, and death of 91·4% (95%CI:90·1-92·5), 91·1% (95%CI:88·9-92·9) and 92·3% (95%CI:90·5-93·7) for Vaxzevria and 71·2% (95%CI:70·0-72·4), 72·2% (95%CI:70·2-74·0) and 73·7% (95%CI:72·1-75·2) for CoronaVac, respectively. VE for all outcomes is progressively lower with age. In fully-Vaxzevria-vaccinated individuals aged <60 years, VE against death was 96.5% (95%CI:82.1-99.3) versus 68·5% (95%CI:40·0-83·4) in those ≥90 years. Among fully-CoronaVac-vaccinated individuals, VE against death was 84.8% (95%CI:77.1-89.9) in those <60 years compared to 63.5 (95%CI 58.7-67.7) for vaccinees aged 80-89 years and 48·6%; (95%CI:35·0-59·3) for individuals aged ≥90 years. Post-vaccination daily cumulative incidence curves for all outcomes showed increased risk from younger to elder decades of life. There was no increase in the incidence of hospitalisation for individuals <60 years vaccinated during the same period as those aged ≥90 years.

Interpretation: Although both vaccines have been effective in protecting against infection, hospitalization and death; Vaxzevria and CoronaVac demonstrated high effectiveness against severe outcomes for individuals up to 79 years of age. Our results reinforce the idea that booster doses should be carefully considered in elders.

Funding: This study was partially supported by a donation from the "Fazer o bem faz bem" program.

Citing Articles

Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection.

Harris A, Kurtovic L, Nogueira J, Bouzas I, Opi D, Wines B Commun Med (Lond). 2024; 4(1):273.

PMID: 39702507 PMC: 11659474. DOI: 10.1038/s43856-024-00686-6.

Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.

Zhang Y, Chen A, Li D, Yuan Q, Zhu A, Deng J NPJ Vaccines. 2024; 9(1):176.

PMID: 39341822 PMC: 11438966. DOI: 10.1038/s41541-024-00971-4.

Estimating All-Cause Deaths Averted in the First Two Years of the COVID-19 Vaccination Campaign in Italy.

Corrao G, Porcu G, Tratsevich A, Cereda D, Pavesi G, Bertolaso G Vaccines (Basel). 2024; 12(4).

PMID: 38675795 PMC: 11055119. DOI: 10.3390/vaccines12040413.

Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol.

Campos G, Almeida N, Filgueiras P, Corsini C, Gomes S, de Miranda D Front Cell Infect Microbiol. 2024; 14:1371695.

PMID: 38638823 PMC: 11024236. DOI: 10.3389/fcimb.2024.1371695.

National epidemiological analysis of the association of COVID-19 vaccination and incidence of COVID-19 cases in Canada, January to August 2021.

Coverage V, System I, Surveillance V Can Commun Dis Rep. 2024; 49(4):145-154.

PMID: 38390393 PMC: 10883463. DOI: 10.14745/ccdr.v49i04a07.

References

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View

Hitchings M, Lewnard J, Dean N, Ko A, Ranzani O, Andrews J . Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of COVID-19 Vaccine Effectiveness. Epidemiology. 2022; 33(4):450-456. PMC: 9148635. DOI: 10.1097/EDE.0000000000001484. View

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

Moghadas S, Vilches T, Zhang K, Wells C, Shoukat A, Singer B . The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin Infect Dis. 2021; 73(12):2257-2264. PMC: 7929033. DOI: 10.1093/cid/ciab079. View

Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta A . Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. 2017; 35(21):2775-2780. DOI: 10.1016/j.vaccine.2017.03.092. View

Chung H, He S, Nasreen S, Sundaram M, Buchan S, Wilson S . Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021; 374:n1943. PMC: 8377789. DOI: 10.1136/bmj.n1943. View

Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D . Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol. 2018; 40:83-94. DOI: 10.1016/j.smim.2018.10.010. View

Victora P, Castro P, Gurzenda S, Medeiros A, Franca G, Barros P . Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine. 2021; 38:101036. PMC: 8283303. DOI: 10.1016/j.eclinm.2021.101036. View

Vasileiou E, Simpson C, Shi T, Kerr S, Agrawal U, Akbari A . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397(10285):1646-1657. PMC: 8064669. DOI: 10.1016/S0140-6736(21)00677-2. View

10.

Osterholm M, Kelley N, Sommer A, Belongia E . Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2011; 12(1):36-44. DOI: 10.1016/S1473-3099(11)70295-X. View

11.

Chodick G, Tene L, Rotem R, Patalon T, Gazit S, Ben-Tov A . The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data. Clin Infect Dis. 2021; 74(3):472-478. PMC: 8240867. DOI: 10.1093/cid/ciab438. View

12.

Frater J, Ewer K, Ogbe A, Pace M, Adele S, Adland E . Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021; 8(8):e474-e485. PMC: 8213361. DOI: 10.1016/S2352-3018(21)00103-X. View

13.

Ranzani O, Hitchings M, Dorion M, DAgostini T, Paula R, de Paula O . Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021; 374:n2015. PMC: 8377801. DOI: 10.1136/bmj.n2015. View

14.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881-891. PMC: 7894131. DOI: 10.1016/S0140-6736(21)00432-3. View

15.

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

16.

Ranzani O, Bastos L, Gelli J, Marchesi J, Baiao F, Hamacher S . Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021; 9(4):407-418. PMC: 7834889. DOI: 10.1016/S2213-2600(20)30560-9. View

17.

Madhi S, Baillie V, Cutland C, Voysey M, Koen A, Fairlie L . Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20):1885-1898. PMC: 7993410. DOI: 10.1056/NEJMoa2102214. View

18.

da Silva S, Pena L . Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil. One Health. 2021; 13:100287. PMC: 8240439. DOI: 10.1016/j.onehlt.2021.100287. View

19.

M L Aquino E, Silveira I, Pescarini J, Aquino R, Souza-Filho J, Rocha A . Social distancing measures to control the COVID-19 pandemic: potential impacts and challenges in Brazil. Cien Saude Colet. 2020; 25(suppl 1):2423-2446. DOI: 10.1590/1413-81232020256.1.10502020. View

20.

Oliveira E, Colosimo E, Simoes E Silva A, Mak R, Martelli D, Silva L . Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database. Lancet Child Adolesc Health. 2021; 5(8):559-568. PMC: 8192298. DOI: 10.1016/S2352-4642(21)00134-6. View